Myriad Genetics is a diagnostics & research business based in the US. Myriad Genetics shares (MYGN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $15.30 – a decrease of 2.42% over the previous week. Myriad Genetics employs 2,700 staff and has a trailing 12-month revenue of around $823.6 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $15.30 |
|---|---|
| 52-week range | $15.18 - $29.30 |
| 50-day moving average | $23.66 |
| 200-day moving average | $23.62 |
| Wall St. target price | $24.92 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.27 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $15 from 2024-11-19
| 1 week (2024-11-14) | -4.34% |
|---|---|
| 1 month (2024-10-21) | -33.45% |
| 3 months (2024-08-21) | -46.29% |
| 6 months (2024-05-21) | -38.47% |
| 1 year (2023-11-21) | -14.19% |
|---|---|
| 2 years (2022-11-21) | -22.40% |
| 3 years (2021-11-19) | 28.06 |
| 5 years (2019-11-21) | 25.11 |
Valuing Myriad Genetics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Myriad Genetics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Myriad Genetics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4001. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Myriad Genetics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $823.6 million |
|---|---|
| Gross profit TTM | $476.4 million |
| Return on assets TTM | -5.35% |
| Return on equity TTM | -16.4% |
| Profit margin | -14.09% |
| Book value | $8.04 |
| Market Capitalization | $1.4 billion |
TTM: trailing 12 months
We're not expecting Myriad Genetics to pay a dividend over the next 12 months.
Myriad Genetics's shares were split on a 2:1 basis on 25 March 2009 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Myriad Genetics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Myriad Genetics shares which in turn could have impacted Myriad Genetics's share price.
Over the last 12 months, Myriad Genetics's shares have ranged in value from as little as $15.18 up to $29.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Myriad Genetics's is 1.937. This would suggest that Myriad Genetics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Myriad Genetics, Inc. , a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.